首页 > 最新文献

JA Clinical Reports最新文献

英文 中文
Tracheal injury diagnosed by a sudden increase in end-tidal carbon dioxide levels during mediastinoscopic subtotal esophagectomy: a case report. 纵隔镜下食管次全切除术中潮气末二氧化碳浓度突然升高导致气管损伤:病例报告。
IF 0.9 Q3 ANESTHESIOLOGY Pub Date : 2024-02-13 DOI: 10.1186/s40981-024-00695-3
Natsuho Haraguchi, Yoshifumi Naito, Masayuki Shibasaki, Teiji Sawa

Background: Mediastinoscopic surgery for esophageal cancer facilitates early postoperative recovery. However, it can occasionally cause serious complications. Here, we present the case of a patient with a tracheal injury diagnosed by a sudden increase in end-tidal carbon dioxide (EtCO2) during mediastinoscopic subtotal esophagectomy.

Case presentation: A 52-year-old man diagnosed with esophageal cancer was scheduled to undergo mediastinoscopic subtotal esophagectomy. During the mediastinoscopic procedure, the EtCO2 level suddenly increased above 200 mmHg, and the blood pressure dropped below 80 mmHg. We immediately asked the operator to stop insufflation and found a tracheal injury on the right side of the trachea near the carina by bronchoscopy. The endotracheal tube was replaced with a double-lumen tube, and the trachea was repaired via right thoracotomy. There were no further intraoperative complications. After surgery, the patient was extubated and admitted to the intensive care unit.

Conclusions: Monitoring EtCO2 levels and close communication with the operator is important for safely managing sudden tracheal injury during mediastinoscopic esophagectomy.

背景:纵隔镜手术治疗食管癌有利于术后早期恢复。然而,它偶尔也会引起严重的并发症。在此,我们介绍了一例在纵隔镜食管次全切除术中因潮气末二氧化碳(EtCO2)突然升高而被诊断为气管损伤的患者:一名被诊断患有食管癌的 52 岁男子计划接受纵隔镜下食管次全切除术。在纵隔镜手术过程中,EtCO2 水平突然升至 200 mmHg 以上,血压降至 80 mmHg 以下。我们立即要求操作员停止充气,并通过支气管镜检查发现气管右侧靠近心窝处有一处气管损伤。我们用双腔管替换了气管导管,并通过右胸腔切开术修复了气管。术中未再出现并发症。术后,患者拔管并进入重症监护室:结论:在纵隔镜食管切除术中,监测EtCO2水平并与操作者密切沟通对于安全处理突发性气管损伤非常重要。
{"title":"Tracheal injury diagnosed by a sudden increase in end-tidal carbon dioxide levels during mediastinoscopic subtotal esophagectomy: a case report.","authors":"Natsuho Haraguchi, Yoshifumi Naito, Masayuki Shibasaki, Teiji Sawa","doi":"10.1186/s40981-024-00695-3","DOIUrl":"10.1186/s40981-024-00695-3","url":null,"abstract":"<p><strong>Background: </strong>Mediastinoscopic surgery for esophageal cancer facilitates early postoperative recovery. However, it can occasionally cause serious complications. Here, we present the case of a patient with a tracheal injury diagnosed by a sudden increase in end-tidal carbon dioxide (EtCO<sub>2</sub>) during mediastinoscopic subtotal esophagectomy.</p><p><strong>Case presentation: </strong>A 52-year-old man diagnosed with esophageal cancer was scheduled to undergo mediastinoscopic subtotal esophagectomy. During the mediastinoscopic procedure, the EtCO<sub>2</sub> level suddenly increased above 200 mmHg, and the blood pressure dropped below 80 mmHg. We immediately asked the operator to stop insufflation and found a tracheal injury on the right side of the trachea near the carina by bronchoscopy. The endotracheal tube was replaced with a double-lumen tube, and the trachea was repaired via right thoracotomy. There were no further intraoperative complications. After surgery, the patient was extubated and admitted to the intensive care unit.</p><p><strong>Conclusions: </strong>Monitoring EtCO<sub>2</sub> levels and close communication with the operator is important for safely managing sudden tracheal injury during mediastinoscopic esophagectomy.</p>","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"10 1","pages":"11"},"PeriodicalIF":0.9,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful radiofrequency thermocoagulation of the mandibular nerve for intractable pain associated with medication-related osteonecrosis of the jaw: a case report. 下颌神经射频热凝术成功治疗药物性下颌骨骨坏死引起的顽固性疼痛:病例报告。
IF 0.9 Q3 ANESTHESIOLOGY Pub Date : 2024-02-13 DOI: 10.1186/s40981-024-00696-2
Sho Shinotsuka, Aiko Maeda, Tomoka Eri, Nozomi Kameyama, Chiaki Yamada, Masako Asada, Ken Yamaura

Background: Bisphosphonates may cause serious adverse events, including osteonecrosis of the jaw. This article describes a case of successful application of radiofrequency thermocoagulation for pain caused by osteonecrosis of the jaw.

Case presentation: An 86-year-old woman who had received alendronate sodium hydrate for osteoporosis was diagnosed with osteonecrosis of the right mandible after dental treatment. Despite repeated conservative and debridement treatments, the patient could not eat due to intractable pain; accordingly, her condition was debilitated. The patient was referred to our pain management clinic for radiofrequency thermocoagulation of the right mandibular nerve. Immediately after the procedure, her pain drastically improved and she could eat; moreover, the pain has not recurred for 3 years.

Conclusion: Our findings demonstrate that minimally invasive radiofrequency thermocoagulation may have long-term effects in patients with chronic pain caused by osteonecrosis of the jaw that is refractory to conservative treatment.

背景:双膦酸盐可能导致严重的不良反应,包括颌骨坏死。本文描述了一例成功应用射频热凝治疗颌骨坏死引起的疼痛的病例:一名 86 岁的妇女因骨质疏松症接受阿仑膦酸钠水合物治疗,在牙科治疗后被诊断为右下颌骨骨坏死。尽管经过反复的保守治疗和清创治疗,但患者仍因疼痛难忍而无法进食;因此,她的病情十分衰弱。患者被转诊到我们的疼痛治疗诊所,接受了右下颌神经射频热凝术。术后,她的疼痛立即得到了明显改善,并能进食;此外,疼痛已持续 3 年未复发:我们的研究结果表明,微创射频热凝术对保守治疗无效的下颌骨骨坏死引起的慢性疼痛患者有长期疗效。
{"title":"Successful radiofrequency thermocoagulation of the mandibular nerve for intractable pain associated with medication-related osteonecrosis of the jaw: a case report.","authors":"Sho Shinotsuka, Aiko Maeda, Tomoka Eri, Nozomi Kameyama, Chiaki Yamada, Masako Asada, Ken Yamaura","doi":"10.1186/s40981-024-00696-2","DOIUrl":"10.1186/s40981-024-00696-2","url":null,"abstract":"<p><strong>Background: </strong>Bisphosphonates may cause serious adverse events, including osteonecrosis of the jaw. This article describes a case of successful application of radiofrequency thermocoagulation for pain caused by osteonecrosis of the jaw.</p><p><strong>Case presentation: </strong>An 86-year-old woman who had received alendronate sodium hydrate for osteoporosis was diagnosed with osteonecrosis of the right mandible after dental treatment. Despite repeated conservative and debridement treatments, the patient could not eat due to intractable pain; accordingly, her condition was debilitated. The patient was referred to our pain management clinic for radiofrequency thermocoagulation of the right mandibular nerve. Immediately after the procedure, her pain drastically improved and she could eat; moreover, the pain has not recurred for 3 years.</p><p><strong>Conclusion: </strong>Our findings demonstrate that minimally invasive radiofrequency thermocoagulation may have long-term effects in patients with chronic pain caused by osteonecrosis of the jaw that is refractory to conservative treatment.</p>","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"10 1","pages":"12"},"PeriodicalIF":0.9,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analgesic effect of neuromodulation using the AT-04 portable magnetic field-generating device in a patient with neuropathic pain: a case report. 使用 AT-04 便携式磁场发生装置对神经病理性疼痛患者进行神经调控的镇痛效果:病例报告。
IF 0.9 Q3 ANESTHESIOLOGY Pub Date : 2024-02-10 DOI: 10.1186/s40981-024-00694-4
Atsushi Sawada, Michiaki Yamakage

Background: Neuromodulation by magnetic field through the AT-04 (ait® (AT-04); Peace of Mind Co., Ltd., Kumamoto, Japan) has improved allodynia in neuropathic pain model rats. This report focuses on neuromodulation through magnetic field exposure using the AT-04 that provided an analgesic effect in a patient with neuropathic pain.

Case presentation: A 47-year-old man presented with flaccid paralysis and extensive neuropathic pain and scored 7 on the 11-point Numerical Rating Scale (NRS) for his left upper limb. The patient was treated with neuromodulation by magnetic field exposure using the AT-04. Baseline NRS scores were obtained three times daily during the baseline period (days 1-5). Magnetic field exposure was then performed for 30 min three times daily (morning, noon, and evening) at home for 36 days, which was termed the intervention period (days 6-41). During the baseline period, the median NRS score was 7 and the baseline NRS score for calculating the percentage of nonoverlap data (PND) was 6. During the intervention period, the median NRS score was 4 and the PND value of the NRS score was 77.8% (28/36). Neuromodulation by magnetic field exposure using the AT-04 effectively decreased the patient's NRS score. The patient had no adverse effects during the intervention period.

Conclusions: Neuromodulation by magnetic field exposure using the AT-04 was effective in decreasing the NRS score in a patient with neuropathic pain. The AT-04 portable magnetic field-generating device shows potential as a therapeutic option for refractory neuropathic pain.

背景:通过 AT-04(ait® (AT-04);Peace of Mind Co., Ltd., Kumamoto, Japan)进行磁场神经调控改善了神经病理性疼痛模型大鼠的异动症。本报告的重点是使用 AT-04 通过磁场照射进行神经调节,从而为一名神经病理性疼痛患者提供镇痛效果:一名 47 岁的男子出现弛缓性瘫痪和广泛的神经病理性疼痛,左上肢在 11 点数字评定量表(NRS)中得分为 7 分。患者接受了使用 AT-04 进行磁场照射的神经调控治疗。在基线期(第 1-5 天),每天三次获得基线 NRS 分数。然后在家中进行磁场照射,每天三次,每次 30 分钟(早、中、晚),持续 36 天,称为干预期(第 6-41 天)。在基线期,NRS 评分的中位数为 7 分,用于计算无重叠数据百分比(PND)的基线 NRS 评分为 6 分;在干预期,NRS 评分的中位数为 4 分,NRS 评分的 PND 值为 77.8%(28/36)。使用 AT-04 通过磁场照射进行神经调控,有效降低了患者的 NRS 评分。患者在干预期间未出现任何不良反应:结论:使用 AT-04 通过磁场照射进行神经调控能有效降低神经病理性疼痛患者的 NRS 评分。AT-04便携式磁场发生装置具有治疗难治性神经病理性疼痛的潜力。
{"title":"Analgesic effect of neuromodulation using the AT-04 portable magnetic field-generating device in a patient with neuropathic pain: a case report.","authors":"Atsushi Sawada, Michiaki Yamakage","doi":"10.1186/s40981-024-00694-4","DOIUrl":"10.1186/s40981-024-00694-4","url":null,"abstract":"<p><strong>Background: </strong>Neuromodulation by magnetic field through the AT-04 (ait® (AT-04); Peace of Mind Co., Ltd., Kumamoto, Japan) has improved allodynia in neuropathic pain model rats. This report focuses on neuromodulation through magnetic field exposure using the AT-04 that provided an analgesic effect in a patient with neuropathic pain.</p><p><strong>Case presentation: </strong>A 47-year-old man presented with flaccid paralysis and extensive neuropathic pain and scored 7 on the 11-point Numerical Rating Scale (NRS) for his left upper limb. The patient was treated with neuromodulation by magnetic field exposure using the AT-04. Baseline NRS scores were obtained three times daily during the baseline period (days 1-5). Magnetic field exposure was then performed for 30 min three times daily (morning, noon, and evening) at home for 36 days, which was termed the intervention period (days 6-41). During the baseline period, the median NRS score was 7 and the baseline NRS score for calculating the percentage of nonoverlap data (PND) was 6. During the intervention period, the median NRS score was 4 and the PND value of the NRS score was 77.8% (28/36). Neuromodulation by magnetic field exposure using the AT-04 effectively decreased the patient's NRS score. The patient had no adverse effects during the intervention period.</p><p><strong>Conclusions: </strong>Neuromodulation by magnetic field exposure using the AT-04 was effective in decreasing the NRS score in a patient with neuropathic pain. The AT-04 portable magnetic field-generating device shows potential as a therapeutic option for refractory neuropathic pain.</p>","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"10 1","pages":"10"},"PeriodicalIF":0.9,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10857986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139712236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vulnerability to bending and occlusion of distal lumen of the 17G triple-lumen central venous catheter 17G 三腔中心静脉导管远端管腔弯曲和闭塞的脆弱性
IF 0.9 Q3 ANESTHESIOLOGY Pub Date : 2024-02-03 DOI: 10.1186/s40981-024-00691-7
Tomohiro Yamamoto
<p>To the Editor</p><p>The risk of central venous catheter (CVC)-related venous thrombosis [1, 2] should always be kept in mind. It is a critical issue, particularly in pediatric patients with congenital heart diseases, because of the possible impact on subsequent surgical treatment. The risk of CVC-related venous thrombosis is reportedly greater when CVC is larger than one-third the diameter of the target vein [3]. Cardinal Health™ has recently developed a 17-gauge (G) triple-lumen CVC (ARGYLE™ Fukuroi SMAC<sup>TM</sup> Plus), of which the cross-sectional area of lumens and flow rate are comparable to those of a 15G triple-lumen CVC (Fig. 1).</p><figure><figcaption><b data-test="figure-caption-text">Fig. 1</b></figcaption><picture><source srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40981-024-00691-7/MediaObjects/40981_2024_691_Fig1_HTML.png?as=webp" type="image/webp"/><img alt="figure 1" aria-describedby="Fig1" height="380" loading="lazy" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40981-024-00691-7/MediaObjects/40981_2024_691_Fig1_HTML.png" width="685"/></picture><p>Cross-section of central venous catheters (CVCs). Cross section of the 17-gauge (G) double-lumen (left), 17G triple-lumen (center), and 15G triple-lumen (right) CVCs (ARGYLE™ Fukuroi SMAC™ Plus, Cardinal Health™), side by side with ruler scale for size comparison. Note the semicircular-shaped distal (largest) lumen of the 17G triple-lumen CVC (center) in contrast with the circular-shaped distal lumens of the 17G double-lumen (left) and of the 15G triple-lumen (right) CVCs. The outer diameters of the 17G double-lumen (left), 17G triple-lumen (center), and 15G double-lumen CVC (right) are 1.35 mm, 1.45 mm, and 1.70 mm, respectively</p><span>Full size image</span><svg aria-hidden="true" focusable="false" height="16" role="img" width="16"><use xlink:href="#icon-eds-i-chevron-right-small" xmlns:xlink="http://www.w3.org/1999/xlink"></use></svg></figure><p>The distal lumen is generally thought to be the least susceptible to catheter bending and the least vulnerable to occlusion because it has the largest lumen and is located in the middle of the catheter. However, uncommonly, we have encountered several cases in our hospital wherein the pressure alarm sounded on the syringe pump connected to the distal lumen or no blood backflow was obtained from the distal lumen of the 17G triple-lumen CVC, whereas the other two smaller lumens had no problems. We found that the CVCs were bent at the site just distal to the junction hub (Fig. 2), which was common in all catheter obstruction cases. However, 17G double-lumen CVCs had been used in our hospital without similar problems. The cross-sectional structure of the CVCs is shown in Fig. 1, where the lumens of the 17G triple-lumen CVC have a semicircular or fan-shaped structure. Additionally, the distal lumen, which has a semicircular structure, is the most vulnerable to bending, while
致编辑应始终牢记中心静脉导管(CVC)相关静脉血栓形成的风险[1, 2]。这是一个至关重要的问题,尤其是对于患有先天性心脏病的儿科患者,因为这可能会影响后续的手术治疗。据报道,当 CVC 的直径大于目标静脉直径的三分之一时,与 CVC 相关的静脉血栓风险更大[3]。Cardinal Health™ 最近开发了一种 17 号三腔 CVC(ARGYLE™ Fukuroi SMACTM Plus),其管腔横截面积和流速与 15 号三腔 CVC 相当(图 1)。17 号 (G) 双腔导管(左)、17 号三腔导管(中)和 15 号三腔导管(右)(ARGYLE™ Fukuroi SMAC™ Plus,Cardinal Health™)的横截面,并排显示,标尺刻度用于尺寸比较。注意 17G 三腔 CVC(中间)的远端(最大)管腔呈半圆形,而 17G 双腔(左)和 15G 三腔(右)CVC 的远端管腔呈圆形。17G 双腔(左)、17G 三腔(中)和 15G 双腔 CVC(右)的外径分别为 1.35 毫米、1.45 毫米和 1.70 毫米全尺寸图片一般认为,远端管腔最不易受导管弯曲的影响,也最不易发生闭塞,因为它的管腔最大,而且位于导管的中间。然而,我们医院曾遇到过几例罕见的情况,即连接远端管腔的注射泵压力警报响起,或者 17G 三腔 CVC 远端管腔没有血液倒流,而其他两个较小的管腔却没有问题。我们发现,在所有导管阻塞病例中,CVC 在连接枢纽的远端都出现了弯曲(图 2)。不过,我们医院使用的 17G 双腔 CVC 也没有出现类似问题。CVC 的横截面结构如图 1 所示,其中 17G 三腔 CVC 的管腔呈半圆形或扇形结构。此外,半圆形结构的远端管腔最容易弯曲,而 17G 双腔和 15G 三腔 CVC 的管腔为圆形或新月形结构。尽管 17G 三腔 CVC 的外径较小,但为了确保管腔较大,导管结构和管腔之间的隔壁比 17G 双腔或 15G 三腔 CVC 的更薄(图 1)。从一个远端管腔堵塞的病例中取出 17G 三腔 CVC 后的照片。请注意,所有远端管腔阻塞的导管在连接枢纽(黑色箭头)远端都会出现急弯。以 SAFE ACCESS™ (Cardinal Health™)输液器的延长管为例(图 3a)。按照之前的描述[4]计算出 CVC 插入深度后,将 SAFE ACCESS™ (Cardinal Health™)输液器的延长管剪切到适当长度,然后将 CVC 穿过延长管,深度足以完全覆盖 CVC 的薄弱部分,即连接枢纽远端(图 3a 中的黑色箭头)。之后,连接固定装置。我们医院的一些麻醉师使用 16 Fr 抽吸管(ARGYLE™ Fukuroi,Cardinal Health™)完全覆盖连接毂(黑色箭头)和固定装置的橡胶部分(白色箭头)(图 3b)。自从这种方法问世以来,我们医院已经彻底解决了 CVC 弯曲和闭塞问题。这种方法可以使用任何机构都能找到的廉价物品,如静脉管路或吸引管。它有助于保护患者,避免因儿茶酚胺剂量不稳定而导致循环不稳定的风险。图 3 插入手术前的加固型 17G 三腔 CVC。™ )输液器的延长管和 b 16 Fr 抽吸管(ARGYLETM Fukuroi,Cardinal HealthTM),覆盖了从连接枢纽(黑色箭头)到固定装置橡胶部分(白色箭头)的 17G 三腔 CVC。儿科心脏重症监护室中与中央静脉导管相关的深静脉血栓形成。J Surg Res. 2019;241:149-59.Article PubMed Google Scholar Kim EH, Lee JH, Kim HS, Jang YE, Ji SH, Kang P, et al. 儿科手术患者中央静脉导管相关血栓形成:前瞻性观察研究。2022;32:563-71.
{"title":"Vulnerability to bending and occlusion of distal lumen of the 17G triple-lumen central venous catheter","authors":"Tomohiro Yamamoto","doi":"10.1186/s40981-024-00691-7","DOIUrl":"https://doi.org/10.1186/s40981-024-00691-7","url":null,"abstract":"&lt;p&gt;To the Editor&lt;/p&gt;&lt;p&gt;The risk of central venous catheter (CVC)-related venous thrombosis [1, 2] should always be kept in mind. It is a critical issue, particularly in pediatric patients with congenital heart diseases, because of the possible impact on subsequent surgical treatment. The risk of CVC-related venous thrombosis is reportedly greater when CVC is larger than one-third the diameter of the target vein [3]. Cardinal Health™ has recently developed a 17-gauge (G) triple-lumen CVC (ARGYLE™ Fukuroi SMAC&lt;sup&gt;TM&lt;/sup&gt; Plus), of which the cross-sectional area of lumens and flow rate are comparable to those of a 15G triple-lumen CVC (Fig. 1).&lt;/p&gt;&lt;figure&gt;&lt;figcaption&gt;&lt;b data-test=\"figure-caption-text\"&gt;Fig. 1&lt;/b&gt;&lt;/figcaption&gt;&lt;picture&gt;&lt;source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40981-024-00691-7/MediaObjects/40981_2024_691_Fig1_HTML.png?as=webp\" type=\"image/webp\"/&gt;&lt;img alt=\"figure 1\" aria-describedby=\"Fig1\" height=\"380\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40981-024-00691-7/MediaObjects/40981_2024_691_Fig1_HTML.png\" width=\"685\"/&gt;&lt;/picture&gt;&lt;p&gt;Cross-section of central venous catheters (CVCs). Cross section of the 17-gauge (G) double-lumen (left), 17G triple-lumen (center), and 15G triple-lumen (right) CVCs (ARGYLE™ Fukuroi SMAC™ Plus, Cardinal Health™), side by side with ruler scale for size comparison. Note the semicircular-shaped distal (largest) lumen of the 17G triple-lumen CVC (center) in contrast with the circular-shaped distal lumens of the 17G double-lumen (left) and of the 15G triple-lumen (right) CVCs. The outer diameters of the 17G double-lumen (left), 17G triple-lumen (center), and 15G double-lumen CVC (right) are 1.35 mm, 1.45 mm, and 1.70 mm, respectively&lt;/p&gt;&lt;span&gt;Full size image&lt;/span&gt;&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/figure&gt;&lt;p&gt;The distal lumen is generally thought to be the least susceptible to catheter bending and the least vulnerable to occlusion because it has the largest lumen and is located in the middle of the catheter. However, uncommonly, we have encountered several cases in our hospital wherein the pressure alarm sounded on the syringe pump connected to the distal lumen or no blood backflow was obtained from the distal lumen of the 17G triple-lumen CVC, whereas the other two smaller lumens had no problems. We found that the CVCs were bent at the site just distal to the junction hub (Fig. 2), which was common in all catheter obstruction cases. However, 17G double-lumen CVCs had been used in our hospital without similar problems. The cross-sectional structure of the CVCs is shown in Fig. 1, where the lumens of the 17G triple-lumen CVC have a semicircular or fan-shaped structure. Additionally, the distal lumen, which has a semicircular structure, is the most vulnerable to bending, while","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"296 2 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139664201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-reply to the comment by Poling et al 回应波林等人的评论
IF 0.9 Q3 ANESTHESIOLOGY Pub Date : 2024-02-03 DOI: 10.1186/s40981-023-00681-1
Kyosuke Takahashi, Kotaro Sakurai, Izumi Hamaya
<p>To the editor</p><p>We thank Poling et al. for their interest in our report [1]. They raised the importance of a new disease concept and optimal management according to the diagnosis.</p><p>As they pointed out, the diagnosis of Freeman-Sheldon syndrome (FSS) (What they call Freeman-Burian syndrome [FBS]) is difficult due to similar physical characteristics between FSS/FBS and Sheldon-Hall syndrome. We think our case was not typical of FSS/FBS. Although she had multiple arthrogryposes and prominent nasolabial folds, microstomia was not severe, midface hypoplasia was mild, and tracheal intubation was easy during anesthesia. However, this does not exclude the diagnosis of FSS/FBS.</p><p>The association between distal arthrogryposis and malignant hyperthermia remains uncertain. An observational study that investigated 73 individuals referred with the diagnosis of FSS revealed that 3 out of 10 patients developed malignant hyperthermia when they had surgery [2]. On the other hand, a study reported no association between malignant hyperthermia and distal arthrogryposis [3]. Considering the mixed findings of past studies, it is still safe to avoid inhalation anesthetics because we have many alternative options without them. Hence, our strategy using propofol, opioids, and dexmedetomidine was a reasonable choice for the patient who underwent cardiac surgery. Further studies with large sample sizes are needed to determine the association between malignant hyperthermia and this syndrome. Until this question is resolved, providing malignant-hyperthermia-safe anesthesia for patients with FSS/FBS is warranted.</p><p>Not applicable.</p><dl><dt style="min-width:50px;"><dfn>FBS:</dfn></dt><dd><p>Freeman Burian Syndrome</p></dd><dt style="min-width:50px;"><dfn>FSS:</dfn></dt><dd><p>Freeman Sheldon Syndrome</p></dd></dl><ol data-track-component="outbound reference"><li data-counter="1."><p>Takahashi K, Sakurai K, Hamaya I. Anesthetic management of a pediatric patient with Freeman-Sheldon syndrome undergoing atrial septal defect closure: a case report. JA Clin Reports Springer, Berlin Heidelberg. 2023;9:9–12. https://doi.org/10.1186/s40981-023-00633-9.</p><p>Article Google Scholar </p></li><li data-counter="2."><p>Stevenson DA, Carey JC, Palumbos J, Rutherford A, Dolcourt J, Bamshad MJ. Clinical characteristics and natural history of Freeman-Sheldon syndrome. Pediatrics. 2006;117:754–62.</p><p>Article PubMed Google Scholar </p></li><li data-counter="3."><p>Gleich SJ, Tien M, Schroeder DR, Hanson AC, Flick R, Nemergut ME. Anesthetic Outcomes of Children with Arthrogryposis Syndromes: No Evidence of Hyperthermia. Anesth Analg. 2017;124:908–14.</p><p>Article PubMed Google Scholar </p></li></ol><p>Download references<svg aria-hidden="true" focusable="false" height="16" role="img" width="16"><use xlink:href="#icon-eds-i-download-medium" xmlns:xlink="http://www.w3.org/1999/xlink"></use></svg></p><p>Not applicable.</p><p>Not applicable.</p><h3>Authors and Affiliatio
1186/s40981-023-00681-1Download citationReceived:27 November 2023Revised: 30 November 2023Accepted:02 December 2023Published: 03 February 2024DOI: https://doi.org/10.1186/s40981-023-00681-1Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
{"title":"In-reply to the comment by Poling et al","authors":"Kyosuke Takahashi, Kotaro Sakurai, Izumi Hamaya","doi":"10.1186/s40981-023-00681-1","DOIUrl":"https://doi.org/10.1186/s40981-023-00681-1","url":null,"abstract":"&lt;p&gt;To the editor&lt;/p&gt;&lt;p&gt;We thank Poling et al. for their interest in our report [1]. They raised the importance of a new disease concept and optimal management according to the diagnosis.&lt;/p&gt;&lt;p&gt;As they pointed out, the diagnosis of Freeman-Sheldon syndrome (FSS) (What they call Freeman-Burian syndrome [FBS]) is difficult due to similar physical characteristics between FSS/FBS and Sheldon-Hall syndrome. We think our case was not typical of FSS/FBS. Although she had multiple arthrogryposes and prominent nasolabial folds, microstomia was not severe, midface hypoplasia was mild, and tracheal intubation was easy during anesthesia. However, this does not exclude the diagnosis of FSS/FBS.&lt;/p&gt;&lt;p&gt;The association between distal arthrogryposis and malignant hyperthermia remains uncertain. An observational study that investigated 73 individuals referred with the diagnosis of FSS revealed that 3 out of 10 patients developed malignant hyperthermia when they had surgery [2]. On the other hand, a study reported no association between malignant hyperthermia and distal arthrogryposis [3]. Considering the mixed findings of past studies, it is still safe to avoid inhalation anesthetics because we have many alternative options without them. Hence, our strategy using propofol, opioids, and dexmedetomidine was a reasonable choice for the patient who underwent cardiac surgery. Further studies with large sample sizes are needed to determine the association between malignant hyperthermia and this syndrome. Until this question is resolved, providing malignant-hyperthermia-safe anesthesia for patients with FSS/FBS is warranted.&lt;/p&gt;&lt;p&gt;Not applicable.&lt;/p&gt;&lt;dl&gt;&lt;dt style=\"min-width:50px;\"&gt;&lt;dfn&gt;FBS:&lt;/dfn&gt;&lt;/dt&gt;&lt;dd&gt;\u0000&lt;p&gt;Freeman Burian Syndrome&lt;/p&gt;\u0000&lt;/dd&gt;&lt;dt style=\"min-width:50px;\"&gt;&lt;dfn&gt;FSS:&lt;/dfn&gt;&lt;/dt&gt;&lt;dd&gt;\u0000&lt;p&gt;Freeman Sheldon Syndrome&lt;/p&gt;\u0000&lt;/dd&gt;&lt;/dl&gt;&lt;ol data-track-component=\"outbound reference\"&gt;&lt;li data-counter=\"1.\"&gt;&lt;p&gt;Takahashi K, Sakurai K, Hamaya I. Anesthetic management of a pediatric patient with Freeman-Sheldon syndrome undergoing atrial septal defect closure: a case report. JA Clin Reports Springer, Berlin Heidelberg. 2023;9:9–12. https://doi.org/10.1186/s40981-023-00633-9.&lt;/p&gt;&lt;p&gt;Article Google Scholar &lt;/p&gt;&lt;/li&gt;&lt;li data-counter=\"2.\"&gt;&lt;p&gt;Stevenson DA, Carey JC, Palumbos J, Rutherford A, Dolcourt J, Bamshad MJ. Clinical characteristics and natural history of Freeman-Sheldon syndrome. Pediatrics. 2006;117:754–62.&lt;/p&gt;&lt;p&gt;Article PubMed Google Scholar &lt;/p&gt;&lt;/li&gt;&lt;li data-counter=\"3.\"&gt;&lt;p&gt;Gleich SJ, Tien M, Schroeder DR, Hanson AC, Flick R, Nemergut ME. Anesthetic Outcomes of Children with Arthrogryposis Syndromes: No Evidence of Hyperthermia. Anesth Analg. 2017;124:908–14.&lt;/p&gt;&lt;p&gt;Article PubMed Google Scholar &lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;Download references&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/p&gt;&lt;p&gt;Not applicable.&lt;/p&gt;&lt;p&gt;Not applicable.&lt;/p&gt;&lt;h3&gt;Authors and Affiliatio","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"10 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139664324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remimazolam in perioperative management of Eisenmenger syndrome: a case report 艾森曼格综合征围手术期治疗中的雷马唑仑:病例报告
IF 0.9 Q3 ANESTHESIOLOGY Pub Date : 2024-02-02 DOI: 10.1186/s40981-024-00692-6
Kazuya Hashimoto, Tsuguhiro Matsumoto, Toshiyuki Mizota, Shinichi Kai, Moritoki Egi
Eisenmenger syndrome (ES) is characterized by severe and irreversible pulmonary hypertension stemming from an uncorrected intracardiac shunt of significant size. The imbalance between systemic and pulmonary artery pressures predisposes patients with ES to the risk of cardiac arrest. Remimazolam has caused less circulatory depression, which may be advantageous for ES. However, no studies reported the use of remimazolam in perioperative ES management. A 45-year-old female patient with ES derived from a ventricular septal defect was scheduled to undergo bilateral adnexectomy for an ovarian tumor. Her oxygen saturation was 80% with 3 L/min oxygen at rest, and her pulmonary and systemic flow ratio was 0.53. She underwent general anesthesia with remimazolam, and intraoperative hemodynamics was stable without hypotension or reduced oxygen saturation. Our successful management of ovarian tumor surgery in a patient with ES using remimazolam reveals its potential effectiveness in perioperative care.
艾森曼格综合征(ES)的特点是严重的、不可逆的肺动脉高压,其根源在于未纠正的心内分流过大。全身压力和肺动脉压力之间的不平衡使 ES 患者面临心脏骤停的风险。雷马唑仑造成的循环抑制较少,这可能对 ES 有利。然而,还没有研究报告称在 ES 的围手术期管理中使用了雷马唑仑。一名因室间隔缺损而患有 ES 的 45 岁女性患者计划接受卵巢肿瘤的双侧附件切除术。她在静息状态下吸氧 3 升/分钟,血氧饱和度为 80%,肺血流与全身血流比为 0.53。她接受了雷马唑仑全身麻醉,术中血流动力学稳定,没有出现低血压或氧饱和度降低。我们使用雷马唑仑成功完成了一名 ES 患者的卵巢肿瘤手术,揭示了雷马唑仑在围手术期护理中的潜在功效。
{"title":"Remimazolam in perioperative management of Eisenmenger syndrome: a case report","authors":"Kazuya Hashimoto, Tsuguhiro Matsumoto, Toshiyuki Mizota, Shinichi Kai, Moritoki Egi","doi":"10.1186/s40981-024-00692-6","DOIUrl":"https://doi.org/10.1186/s40981-024-00692-6","url":null,"abstract":"Eisenmenger syndrome (ES) is characterized by severe and irreversible pulmonary hypertension stemming from an uncorrected intracardiac shunt of significant size. The imbalance between systemic and pulmonary artery pressures predisposes patients with ES to the risk of cardiac arrest. Remimazolam has caused less circulatory depression, which may be advantageous for ES. However, no studies reported the use of remimazolam in perioperative ES management. A 45-year-old female patient with ES derived from a ventricular septal defect was scheduled to undergo bilateral adnexectomy for an ovarian tumor. Her oxygen saturation was 80% with 3 L/min oxygen at rest, and her pulmonary and systemic flow ratio was 0.53. She underwent general anesthesia with remimazolam, and intraoperative hemodynamics was stable without hypotension or reduced oxygen saturation. Our successful management of ovarian tumor surgery in a patient with ES using remimazolam reveals its potential effectiveness in perioperative care.","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"46 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139664213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report. 用甲磺酸萘莫司他治疗一名因斯坦福A型急性主动脉夹层而接受主动脉弓全修补术的患者因安达信α引起的肝素抵抗:病例报告。
IF 0.8 Q3 ANESTHESIOLOGY Pub Date : 2024-01-29 DOI: 10.1186/s40981-024-00690-8
Yasuhito Suzuki, Mutsuhito Kikura, Shingo Kawashima, Tetsuro Kimura, Yoshiki Nakajima

Background: Andexanet alfa, an anti-Xa inhibitor antagonist, induces heparin resistance. Here, we report a case of successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesylate.

Case presentation: An 84-year-old female, with Stanford type A acute aortic dissection, underwent an emergency surgery for total aortic arch replacement. Andexanet alfa 400 mg was administered preoperatively to antagonize edoxaban, an oral Xa inhibitor. Heparin 300 IU/kg was administered before cardiopulmonary bypass, and the activated clotting time (ACT) was 291 s. The ACT was 361 s after another administration of heparin 200 IU/kg. According to our routine therapy for heparin resistance, an initial dose of nafamostat mesylate 10 mg was administered intravenously, followed by a continuous infusion of 20-30 mg/h. The ACT was prolonged to 500 s, and cardiopulmonary bypass was successfully established thereafter.

Conclusions: This case report presents the successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesilate. This report presents the successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesilate.

背景抗 Xa 抑制剂拮抗剂 Andexanet alfa 会诱发肝素抵抗。在此,我们报告了一例使用甲磺酸萘莫司他成功治疗心肺旁路手术中安达沙奈α诱导的肝素抵抗的病例:病例介绍:一名 84 岁的女性患有斯坦福 A 型急性主动脉夹层,接受了全主动脉弓置换的急诊手术。术前给予安达沙尼α 400 毫克,以拮抗口服 Xa 抑制剂埃多沙班。心肺旁路术前给予肝素 300 IU/kg,活化凝血时间(ACT)为 291 秒。根据我们治疗肝素抵抗的常规方法,首先静脉注射甲磺酸萘莫司他 10 毫克,然后每小时持续输注 20-30 毫克。ACT延长至500秒,随后成功建立了心肺旁路:本病例报告介绍了使用甲磺酸萘莫司他成功处理安克沙奈α诱导的肝素抵抗的心肺旁路治疗。本病例报告介绍了使用甲磺酸萘莫司他成功治疗安达沙奈α诱导的肝素抵抗的心肺旁路术。
{"title":"Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report.","authors":"Yasuhito Suzuki, Mutsuhito Kikura, Shingo Kawashima, Tetsuro Kimura, Yoshiki Nakajima","doi":"10.1186/s40981-024-00690-8","DOIUrl":"10.1186/s40981-024-00690-8","url":null,"abstract":"<p><strong>Background: </strong>Andexanet alfa, an anti-Xa inhibitor antagonist, induces heparin resistance. Here, we report a case of successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesylate.</p><p><strong>Case presentation: </strong>An 84-year-old female, with Stanford type A acute aortic dissection, underwent an emergency surgery for total aortic arch replacement. Andexanet alfa 400 mg was administered preoperatively to antagonize edoxaban, an oral Xa inhibitor. Heparin 300 IU/kg was administered before cardiopulmonary bypass, and the activated clotting time (ACT) was 291 s. The ACT was 361 s after another administration of heparin 200 IU/kg. According to our routine therapy for heparin resistance, an initial dose of nafamostat mesylate 10 mg was administered intravenously, followed by a continuous infusion of 20-30 mg/h. The ACT was prolonged to 500 s, and cardiopulmonary bypass was successfully established thereafter.</p><p><strong>Conclusions: </strong>This case report presents the successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesilate. This report presents the successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesilate.</p>","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"10 1","pages":"6"},"PeriodicalIF":0.8,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10825097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between intraoperative blood salvage and coagulation disorder after cardiopulmonary bypass. 心肺旁路术后术中抢救血液与凝血功能障碍之间的关系。
IF 0.8 Q3 ANESTHESIOLOGY Pub Date : 2024-01-25 DOI: 10.1186/s40981-024-00689-1
Masahiro Morinaga, Kenji Yoshitani, Soshiro Ogata, Satsuki Fukushima, Hitoshi Matsuda

Background: This study investigated whether intraoperative blood salvage was associated with coagulation disorder diagnosed by conventional coagulation tests and thromboelastography (TEG) after cardiopulmonary bypass (CPB).

Study design and methods: This was a prospective, observational study. Ninety-two patients who underwent cardiovascular surgery with CPB were enrolled. We evaluated coagulation function in patients with or without cell salvage blood transfusion at the following time points: before CPB, just after protamine administration, and 1 h after protamine administration. We evaluated platelet count, fibrinogen concentration, and TEG parameters. Patients were considered to have coagulation disorder if one or more of the following criteria were present: (1) residual heparin, (2) low platelet count, (3) low fibrinogen level, (4) low clotting factor level, and (5) hyperfibrinolysis.

Results: Fifty-three of 92 patients (57.6%) received intraoperative cell salvage. Coagulation disorder was observed in 56 of 92 patients (60.9%) after CPB. There was no significant difference between patients with or without intraoperative blood salvage in terms of the incidence of coagulation disorder (p = 0.542) or the total volume of blood from the drain after CPB (p = 0.437). Intraoperative blood salvage was not associated with coagulation disorder diagnosed by either TEG or conventional coagulation tests (odds ratio 1.329, 95% confidence interval: 0.549-3.213, p = 0.547). There were no significant interactions between patients with or without intraoperative blood salvage regarding coagulation parameters derived from TEG.

Conclusions: The incidence of coagulation disorder and the total blood volume from the drain after CPB did not differ significantly between patients with or without intraoperative blood salvage.

背景:本研究探讨了心肺旁路术(CPB)后,术中血液抢救是否与通过常规凝血测试和血栓弹性成像(TEG)诊断出的凝血功能障碍有关:这是一项前瞻性观察研究。研究设计:这是一项前瞻性观察研究,共纳入了 92 名使用 CPB 进行心血管手术的患者。我们在以下时间点对接受或未接受细胞挽救输血的患者的凝血功能进行了评估:CPB 前、使用原胺后和使用原胺后 1 小时。我们评估了血小板计数、纤维蛋白原浓度和 TEG 参数。如果存在以下一个或多个标准,则认为患者存在凝血功能障碍:(1)肝素残留;(2)血小板计数低;(3)纤维蛋白原水平低;(4)凝血因子水平低;(5)纤溶亢进:92 例患者中有 53 例(57.6%)接受了术中细胞挽救。92 例患者中有 56 例(60.9%)在 CPB 后出现凝血障碍。就凝血障碍发生率(P = 0.542)或 CPB 后引流管总血量(P = 0.437)而言,接受或未接受术中血液挽救的患者之间无明显差异。术中血液抢救与通过 TEG 或传统凝血测试诊断出的凝血功能障碍无关(几率比 1.329,95% 置信区间:0.549-3.213,p = 0.547)。通过 TEG 得出的凝血参数在有无术中血液挽救的患者之间没有明显的相互作用:结论:CPB术后凝血功能障碍的发生率和引流管总血量在有无术中血液抢救的患者之间没有明显差异。
{"title":"Association between intraoperative blood salvage and coagulation disorder after cardiopulmonary bypass.","authors":"Masahiro Morinaga, Kenji Yoshitani, Soshiro Ogata, Satsuki Fukushima, Hitoshi Matsuda","doi":"10.1186/s40981-024-00689-1","DOIUrl":"10.1186/s40981-024-00689-1","url":null,"abstract":"<p><strong>Background: </strong>This study investigated whether intraoperative blood salvage was associated with coagulation disorder diagnosed by conventional coagulation tests and thromboelastography (TEG) after cardiopulmonary bypass (CPB).</p><p><strong>Study design and methods: </strong>This was a prospective, observational study. Ninety-two patients who underwent cardiovascular surgery with CPB were enrolled. We evaluated coagulation function in patients with or without cell salvage blood transfusion at the following time points: before CPB, just after protamine administration, and 1 h after protamine administration. We evaluated platelet count, fibrinogen concentration, and TEG parameters. Patients were considered to have coagulation disorder if one or more of the following criteria were present: (1) residual heparin, (2) low platelet count, (3) low fibrinogen level, (4) low clotting factor level, and (5) hyperfibrinolysis.</p><p><strong>Results: </strong>Fifty-three of 92 patients (57.6%) received intraoperative cell salvage. Coagulation disorder was observed in 56 of 92 patients (60.9%) after CPB. There was no significant difference between patients with or without intraoperative blood salvage in terms of the incidence of coagulation disorder (p = 0.542) or the total volume of blood from the drain after CPB (p = 0.437). Intraoperative blood salvage was not associated with coagulation disorder diagnosed by either TEG or conventional coagulation tests (odds ratio 1.329, 95% confidence interval: 0.549-3.213, p = 0.547). There were no significant interactions between patients with or without intraoperative blood salvage regarding coagulation parameters derived from TEG.</p><p><strong>Conclusions: </strong>The incidence of coagulation disorder and the total blood volume from the drain after CPB did not differ significantly between patients with or without intraoperative blood salvage.</p>","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"10 1","pages":"5"},"PeriodicalIF":0.8,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10810763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative anaphylaxis with no identifiable cause. 无法确定原因的围手术期过敏性休克。
IF 0.9 Q3 ANESTHESIOLOGY Pub Date : 2024-01-23 DOI: 10.1186/s40981-024-00688-2
Tatsuo Horiuchi, Tomonori Takazawa
{"title":"Perioperative anaphylaxis with no identifiable cause.","authors":"Tatsuo Horiuchi, Tomonori Takazawa","doi":"10.1186/s40981-024-00688-2","DOIUrl":"10.1186/s40981-024-00688-2","url":null,"abstract":"","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"10 1","pages":"3"},"PeriodicalIF":0.9,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10803722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139519296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: anesthetic management of a pediatric patient with Freeman-Sheldon syndrome undergoing atrial septal defect closure: a case report. 评论:一名患有 Freeman-Sheldon 综合征的儿科患者接受房间隔缺损闭合术的麻醉管理:病例报告。
IF 0.9 Q3 ANESTHESIOLOGY Pub Date : 2024-01-23 DOI: 10.1186/s40981-023-00668-y
Mikaela I Poling, Craig R Dufresne
{"title":"Comment on: anesthetic management of a pediatric patient with Freeman-Sheldon syndrome undergoing atrial septal defect closure: a case report.","authors":"Mikaela I Poling, Craig R Dufresne","doi":"10.1186/s40981-023-00668-y","DOIUrl":"10.1186/s40981-023-00668-y","url":null,"abstract":"","PeriodicalId":14635,"journal":{"name":"JA Clinical Reports","volume":"10 1","pages":"4"},"PeriodicalIF":0.9,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10805753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139519137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JA Clinical Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1